Antisense oligonucleotides: a novel Frontier in pharmacological strategy

Frontiers·Nov 16

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Antisense oligonucleotides are being explored as a new approach in pharmacological strategy. They appear to have potential applications in treating various diseases, including rare genetic disorders, als, and cancer. The use of antisense oligonucleotides in therapy is an area of ongoing research, with studies investigating their effectiveness and potential for broad use.

Full coverage

Emerging Modalities in Therapeutics: A Comprehensive Guide to the Future of Drug Discovery

Drug Discovery News·Oct 22

Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS

Nature·Aug 26

Letter by Gu et al Regarding Article, “Antisense Oligonucleotide Therapy for Calmodulinopathy”

American Heart Association Journals·May 5

Case Report: Dominant deafness-onychodystrophy syndrome and hypokalemic periodic paralysis in a single patient: a rare syndromic overlap

Frontiers·Dec 29

How ASOs have revolutionized the treatment of particularly rare and genetically driven or inherited disease?

Servier·Feb 28

Scaling haplospecific antisense oligonucleotides from N-of-1 to broad use in genetic disease populations by diplotyping

medRxiv·Feb 4

Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress

ScienceDirect.com·Sep 10

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

Nature·Mar 10

View original report at Frontiers ↗

Fetching the latest headlines…